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Abstract
Background: HIV vaccine development must address the genetic diversity and plasticity of the virus that permits
the presentation of diverse genetic forms to the immune system and subsequent escape from immune pressure.
Assessment of potential HIV strain coverage by candidate T cell-based vaccines (whether natural sequence or
computationally optimized products) is now a critical component in interpreting candidate vaccine suitability.
Methods: We have utilized an N-mer identity algorithm to represent T cell epitopes and explore potential
coverage of the global HIV pandemic using natural sequences derived from candidate HIV vaccines. Breadth (the
number of T cell epitopes generated) and depth (the variant coverage within a T cell epitope) analyses have been
incorporated into the model to explore vaccine coverage requirements in terms of the number of discrete T cell
epitopes generated.
Results: We show that when multiple epitope generation by a vaccine product is considered a far more nuanced
appraisal of the potential HIV strain coverage of the vaccine product emerges. By considering epitope breadth and
depth several important observations were made: (1) epitope breadth requirements to reach particular levels of
vaccine coverage, even for natural sequence-based vaccine products is not necessarily an intractable problem for
the immune system; (2) increasing the valency (number of T cell epitope variants present) of vaccine products
dramatically decreases the epitope requirements to reach particular coverage levels for any epidemic; (3)
considering multiple-hit models (more than one exact epitope match with an incoming HIV strain) places a
significantly higher requirement upon epitope breadth in order to reach a given level of coverage, to the point
where low valency natural sequence based products would not practically be able to generate sufficient epitopes.
Conclusions: When HIV vaccine sequences are compared against datasets of potential incoming viruses important
metrics such as the minimum epitope count required to reach a desired level of coverage can be easily calculated.
We propose that such analyses can be applied early in the planning stages and during the execution phase of a
vaccine trial to explore theoretical and empirical suitability of a vaccine product to a particular epidemic setting.
Background
Despite advances in therapeutic and prevention cam-
paigns an estimated 33.4 million people currently live
with HIV/AIDS and in 2008 alone, an estimated 2.7 mil-
lion new infections occurred [1]. It is therefore generally
accepted that controlling the global HIV pandemic will
require a successful HIV/AIDS vaccine [2-5]. The design
of an effective HIV vaccine is a multifaceted challenge
involving the development of novel vectors, adjuvants
and antigen design and formulation strategies. The elici-
tation of HIV-specific CD4
+ and/or CD8
+ T cells is con-
sidered an essential component of any potentially
efficacious vaccination strategy [4,6-8]. Such cells could
act as direct effectors in limiting virus replication, or as
helper cells facilitating other effector mechanisms
[9-13]. While a comprehensive review of the evidence
supporting a T cell based HIV vaccine is beyond the
scope of this introduction, a T cell based vaccine should
preferably elicit an immune response capable of prevent-
ing infection or, at a minimum, result in control of viral
replication after infection [14-16]. The recent Thai
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a vaccine that may require appropriate T cell help its
protective effect through adequate antibody generation
[17].
T cells recognize virally infected target cells or anti-
gen-presenting cells via T cell receptor binding to short
peptides (typically 8-12 amino acids in length) presented
in the context of HLA class I or class II alleles [18-21].
It is the exquisite specificity of this interaction that
determines activation and subsequent function of the T
cell [22-24]. Since even a single conservative amino acid
substitution within an epitope may alter or ablate appro-
priate T cell function, it becomes readily apparent why
viral genetic diversity is foremost of the many daunting
obstacles that have impeded the successful development
of an HIV vaccine. The ability of HIV-1 to mutate and
rapidly evolve to evade host immune pressure is
mediated by an error-prone reverse transcriptase,
genetic recombination and the host-derived APOBEC
editing enzymes [25-28]. Due to the vast diversity of
potential challenge viruses that constitute the global
HIV-1 pandemic much effort recently has been focused
on designing vaccine insert sequences to reduce the
impact of viral diversity. These approaches include, but
are not limited to, synthetic constructs that result in
conserved minimal epitope (polyepitope) and conserved
element concatenation into pseudoprotein strings, com-
putationally derived constr u c t ss u c ha sc o n s e n s u s ,
ancestral, center-of-tree and mosaic sequences, as well
as cocktails of natural sequences derived directly from
HIV-1 [26,29-41]. Regardless of which of these insert
design strategies ultimately proves to be the most suc-
cessful, the critical question of how best to assess and
impartially compare these products in pre-clinical stu-
dies or the setting of a vaccine trial remains open.
While several reviews, studies and experimental
approaches have focused on how to deal with the ques-
tion of viral diversity in the context of immunogen
design, to date no study has focused upon how diversity
coverage may be meaningfully assessed in the setting of
an HIV vaccine trial [26,32,34,39,42].
Mounting data suggests that the breadth (number of
discrete epitopes) and depth (amount of epitope variants
recognized) of the T cell response is an important deter-
minant of both HIV pathogenesis and primate model
SIV vaccine efficacy. Multiple studies have recently indi-
cated that it is the breadth of the T cell response rather
than the magnitude, which correlates best with viral
load set point in chronic HIV infection [43-50]. In addi-
tion a seminal study in the rhesus macaque SIV model
demonstrated that immune control of an SIV challenge
by a T cell-based vaccine was correlated with the
breadth of vaccine generated T cell responses [51]. The
fundamental premise of this study was to determine the
extent of coverage a particular vaccine product would
provide for either the global HIV pandemic or for the
homologous subtype from which the product was
derived, and to assess the relationship between epitope
breadth and depth, and vaccine coverage. In this study,
it is shown that by incorporating epitope breadth and
depth analysis into vaccine coverage assessment, metrics
can be used to determine the suitability of a particular
vaccine formulation for a given setting. Parameters such
as the level of coverage of possible incoming HIV-1
strains (75%, 90% or 95%), the sample set of possible
strains (single subtype versus global group M) and the
number of desired exact epitopes matches with an
incoming strain (1-, 2-, or 3-hit models) are all shown
to place dramatically different requirements upon epi-
tope breadth. Furthermore, increasing the valency (num-
ber of included HIV-derived inset sequences) of the
vaccine formulation is shown to dramatically increase
the breadth of coverage and that for even natural
sequence-based products, coping with the enormous
genetic diversity of HIV may not be a totally intractable
problem. While this study has focused upon extant nat-
ural sequence-based vaccine products that are currently
under development, the analysis presented could easily
be performed on new generation computationally
derived vaccine products. Not only does this approach
provide an empirical assessment of vaccine coverage
potential based upon the formulation, but it also allows
direct theoretical comparison of vaccine products as
they might apply to a particular epidemic of HIV-1.
Finally, using example data from a vaccine trial it is
shown that the theoretical calculations compare well
with the experimentally generated data.
Methods
Query sequences and test datasets
The source of all natural HIV-derived Gag and Env pro-
tein query sequences used in the study were a series of
recombinant modified vaccinia Ankara (rMVA) con-
structs that have been developed at the Military HIV
Research Program (MHRP) [31]. Each product contains
an a t i v egag/pol open reading frame and a native env
open reading frame with a C-terminal truncation of
gp41 to maximize expression. The products are based
upon isolates representing subtype A (MVA-KEA), sub-
type C (MVA-TZC), subtype D (MVA-UGD), and
CRF01_AE (MVA-CMDR). Additional File 1 describes
each product in detail together with the isolate sequence
of origin and GenBank accession number. Test sequence
datasets were obtained from the Los Alamos National
Laboratory HIV Sequence Database http://www.hiv.lanl.
gov/content/sequence/HIV/mainpage.html using the
2009 alignments for HIV-1. The final sequence sets
were filtered to remove all N- and O-group and Cpz
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a dataset without bias for subtype or recombinant form
inclusion. The final Gag and Env query datasets con-
sisted of 3585 and 2258 sequences respectively.
Calculation of T cell-based vaccine coverage potential
To quantify the coverage that a particular HIV vaccine
insert may provide in terms of T cell recognition an N-
mer identity approach was used to scan for epitope
matches between vaccine product test sequences and a
query dataset of global M-Group and subtype-specific
HIV Gag and Env sequences. For the purposes of this
study epitopes are defined as 10 amino acids in length
since this represents a reasonable compromise between
the median CD8
+ T cell epitope length (9-10 amino
acids) and the minimal core of a CD4
+ T cell epitope
(10-12 amino acids). The Epicover algorithm (epitope
coverage assessment tool; [32,52]) as implemented in
the LANL HIV Sequence Database http://www.hiv.lanl.
gov/content/sequence/MOSAIC/epicover.html was used
to calculate the proportion of HIV Gag or Env isolate
sequences from the query datasets above which have an
exact 10-mer match with a given vaccine sequence, or
cocktail of sequences. Analysis of exact matches occurs
by dividing the query sequence(s) into all possible 10-
mers (the vaccine “epitome”), then walking each 10-mer
along the test sequences in one amino acid “windows”
and scoring each test sequence for a hit (1), or no hit
(0). The coverage potential of the vaccine is then
expressed as a percentage (or fraction) of sequences in
the test dataset for which an exact 10-mer match is
made. Epicover calculates and expresses coverage as the
mean coverage of N-mers from all test sequences and is
not a strict “hit/no-hit” model of N-mer matching for
each individual sequence. As shown in Additional File 2,
Epicover produces virtually identical results to a strict
“hi/no-hit” algorithm when a sufficiently large dataset is
used and the query sequence dataset (vaccine cocktail)
produces a near Gaussian distribution of random N-mer
matches with the test sequence dataset.
Calculation of epitope requirements for vaccine coverage
The above calculation of vaccine coverage assumes that
each vaccine is capable of generating only a single T cell
epitope, which in both theoretical and practical terms is
not the case. Incorporation breadth (number of discrete
epitopes) and depth (amount of epitope variants recog-
nized) of epitope recognition into the vaccine coverage
analysis is performed at two stages. Depth was included
in the epitope coverage analysis above by considering
multivalent vaccines and each of the different epitope
variants they might present. Analysis of breadth was
included by considering the total number of epitopes
that may be generated by a given vaccine modality. To
integrate the capacity of vaccines to generate multiple
epitopes into the analysis, the following calculation was
used:
p(n)=p(n − 1) + p(n − 1) × (1 − p(n − 1)
Where: n is the number of epitopes generated by a
vaccine
p is the probability of an exact hit on the query
dataset
This calculation can be iterated for as many epitopes
as considered practically possible for a vaccine. The
initial p(n-1) value for the formula is derived from the
Epicover calculation for single epitope coverage. The
resulting coverage potential of a vaccine should there-
fore increase as the breadth and depth of the T cell
response increases. Positional coverage analysis was per-
formed by aligning the LANL 2009 Gag dataset to the
HXB2 reference sequence and performing gap stripping
where necessary to maintain the consensus sequence.
Coverage provided at each of 493 10-mer windows
across the 502 amino acid Gag HXB2 was plotted on a
frequency histogram and examples “low” and “high”
depth of coverage epitopes were annotated.
Calculation of epitope requirements for vaccine coverage
using “multiple hit requirement” models
The prior analyses all work on the implicit assumption
that a single exact epitope match (or “hit”) on a poten-
tial incoming strain of HIV-1 will be sufficient for vac-
cine efficacy. This assumption may be flawed if we
consider that more than one exact match with a
potential incoming strain of virus may be required.
Such a requirement can be thought of in terms of a
“multiple hit” model where two or more exact epitope
matches are required with any incoming strain of virus
for killing of the infected cell or inhibition of virus
replication and preventing viral escape. This model is
best described using the exact binomial probability cal-
culation:




Where: k = the number of exact epitope matches
required (or hits)
N = the actual number of epitopes generated by a
vaccine
p = probability that a single exact epitope match
occurs
q = probability that a single exact epitope match
does not occur
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smaller than N and summing the values yields the prob-
ability of getting at least the required number of exact
matches (hits) for any given epitope count. For example,
when considering a 3-hit model, the probability of at
least 3 exact matches with a vaccine that generates 10
epitopes would be calculated by:






For the purpose of simplicity the two-hit and three-hit
models are considered for this study, however the mod-
els could be extended to four-hit or five-hits if empirical
data supported this requirement.
Application of breadth and depth analysis and multi-hit
models of vaccine coverage to assessment of vaccine trial
data
To demonstrate the application of breadth and depth
analysis in the setting of a vaccine trial, a responder sub-
ject from a recently completed trial of the MVA-CMDR
vaccine product (RV158; [53]) was assessed for breadth
and depth of HIV-specific T cell responses. Briefly, 2
week in vitro stimulated PBMC cultures were estab-
lished as previously described to generate effector cells
for assessing HIV-specific cytotoxic activity [53]. The
effector cells from a positive responder to both Gag and
Env were then epitope mapped using a matrix of pep-
tides matching the Gag and Env insert sequences of
MVA-CMDR using and IFN-g ELISPOT assay.
Responses were de-convoluted and the identified epi-
topes enumerated and subjected to analysis for depth of
coverage using the Epicover algorithm (epitope coverage
assessment tool; [32,52]). The breadth of the response
was used to determine coverage potential of homolo-
gous subtype (CRF01_AE) and the global group M epi-
demic as described above.
Results
Epitope breadth requirements for coverage of the global
group M HIV-1 database with natural sequence constructs
Initially the global HIV-1 group M coverage that would
be provided by the Gag and Env natural sequence
inserts in the MHRP rMVA product development pipe-
line was determined (tabulated in Additional File 1). As
stated in the Methods section 10-mer amino acid win-
dows were defined as the epitope length unit for this
study. The Epicover algorithm (LANL HIV Database)
was then used to determine the theoretical coverage
provided a single epitope generated by the Gag or Env
sequences in each vaccine product for the global M-
group pandemic (3585 Gag sequences; 2258 Env
sequences). The exact 10-mer epitope coverage provided
by the four natural Gag sequences ranged from 21.3% to
3 1 . 0 % ,w h i l et h ec o v e r a g ep r o v i d e db yt h ef o u rE n v
sequences ranged from 13.7% - 15.7% (Figure 1A and
1B; green bars). This is in agreement with the published
data of Korber et al [26] for analysis of individual nat-
ural sequences for coverage of the LANL HIV Database
datasets. Subsequently, the coverage provided by all pos-
sible multivalent combinations (di-, tri- and tetravalent)
was calculated for the 4 Gag and Env natural sequences.
As would be predicted the coverage potential of the
multivalent cocktails increases as the valency increases
due to the unique diversity of each individual construct.
The coverage range increases to 30.4% - 42.0% for the
divalent Gag cocktails (Figure 1A, blue bars), to 39.2% -
46.9% for the trivalent Gag cocktails (Figure 1A, pink
bars), while the tetravalent Gag cocktails present the
greatest coverage potential of 48.7% (Figure 1A, red
bar). Similar increases in coverage potential were seen
for the Env natural sequence cocktails (Figure 1B). Due
to the remarkable diversity of group M Env proteins,
coverage potential is limited to 29.2% for the tetravalent
Env cocktail.
This analysis assumes that a single epitope is gener-
ated by the vaccine construct/cocktail in question.
Increasing the breadth or total number of epitopes gen-
erated by a given vaccine construct amplifies the cover-
age potential dramatically. Figures 1C and 1D show the
theoretical coverage potential of all mono-, di-, tri- and
tetravalent formulations for the Gag and Env natural
sequences respectively. Coverage is shown for the vac-
cines generating a range of 1 through 20 discrete T cell
epitopes. This represents the boundaries of a practical
range of possible discrete T cell epitopes that a vaccine
might be able to generate. It can be seen that a point of
diminishing return is eventually reached for each curve
as it becomes asymptotic with the theoretical limit.
Using such an analysis it is possible to set a limit of
minimal coverage that would be required for a vaccine
product to achieve. In the case shown here (and used
throughout this analysis) a coverage limit of 90% has
been applied. By interpolating along the coverage
requirement for a vaccine, the epitope count that is
required to meet or exceed this requirement can be cal-
culated. Figures 2A and 2B show examples of interpolat-
ing the minimal epitope count required to meet 90%
coverage of any incoming M-group isolate of HIV-1 for
the Gag and Env natural isolates respectively. The exam-
ples shown here highlight the clear advantage that a
multi-valent cocktail provides when compared with a
mono-valent product. When considering Gag-specific
responses the mono-valent subtype A natural sequence
would need to generate a median of 10 epitopes per
subject to reach 90% coverage of the global M-group
dataset, whereas the tetra-valent cocktail would achieve
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per subject (Figure 2A). Due to greater envelope
sequence diversity the epitope requirements to reach
90% coverage are increased to 7 epitopes for the tetra-
valent cocktail and 16 epitopes for the mono-valent sub-
type A natural sequence (Figure 2B). As predicted by
the coverage potential calculations, the epitope require-
ments to reach 90% coverage of the global M-group
dataset decreases as the vaccine valency increases for
both Gag and Env respectively (Figures 2C and 2D).
The multi-valent cocktails provide better coverage with
fewer epitopes due to the presence of different epitope
variants in the individual isolate sequences. The increase
in depth of coverage of any given epitope derives from a
greater number of epitope variants contained in higher
valency formulations. This means that for a given vac-
cine sequence and valency and a given dataset repre-
senting the diversity of potential incoming viruses, a
median epitope count threshold can be set as an
important metric for measuring and comparing candi-
date HIV vaccines.
Consideration of multiple hit requirements for T cell-
based HIV vaccines
The prior analysis is predicated on the notion that a sin-
gle T cell epitope match with an incoming strain of HIV
would be sufficient for recognition of an infected target
cell and prevention of productive infection. While con-
ceptually valid this assumption may be an over simplifi-
cation of the complexities of antigen processing and
presentation and the differential kinetics of viral protein
expression, viral epitope entropy and the TCR reper-
toire. Hence, some epitopes may provide more effective
protection or control of HIV infection than others and
so the chances of eliciting a response against a “good”
epitope increases as the breadth of the response
increases. To incorporate this potential constraint into
the assessment of epitope requirements for T cell-based
Figure 1 Epitope coverage for four Gag and Env natural sequence products. Epitope coverage analysis (exact 10-mer window matching) is
shown for four different natural sequence Gag and Env protein-based vaccine products. Mean coverage of the global HIV-1 group M Gag (3585
sequences) and Env (2258 sequences) datasets obtained from the LANL HIV Database is shown as a percentage of the possible incoming
isolates for which there would be an exact match at any 10-mer window (Panels A and B). Green bars represent the mono-valent Gag and Env
sequences, while the blue, pink and red bars represent all possible di-valent, tri-valent and tetra-valent formations of the four individual products
respectively. Based upon this analysis, the coverage that each formulation would provide was calculated and plotted for up to 20 T cell epitopes
(Panels C and D). Color coding of the lines matches panels A and B above (green for mono-valent, blue for di-valent, pink for tri-valent and red
for tetra-valent). The point at which each formulation achieves 90% coverage of all isolates in the LANL database is denoted by the dotted line.
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analysis. Using such a model, two or more exact epitope
matches would be required with any incoming strain of
virus for vaccine efficacy. As described in the Methods
section this model is a generalized “k“ out of “N“ type
problem and can be described by exact binomial prob-
ability calculations. To illustrate how the requirement
for multiple exact epitope hits impacts the overall epi-
tope breadth requirement for vaccine coverage, the
mono-valent CRF01_AE natural sequence (MVA-CMDR
Gag and Env inserts) were first assessed for coverage of
the homologous subtype (88 Gag sequences and 112
Env sequences from the 2010 LANL database). As
shown in Figure 3 (panels A and B), the coverage of
both Gag and Env are appreciably impacted as the exact
hit requirement increases. In the example shown, the
number of epitopes required to reach 90% coverage of
the CRF01_AE Gag dataset increases from 3 to 6 to 8
epitopes as 1-, 2- and 3-hit models are considered
respectively. For 90% coverage of the CRF01_AE Env
dataset the epitope requirements increase even more
dramatically from 5 to 9 to 12 epitopes for the 1-, 2-
and 3-hit models respectively. When a tetra-valent for-
mulation of the four vaccine products is considered for
coverage of the global Gag and Env datasets (3585 Gag
sequences; 2258 Env sequences) the impact of the multi-
ple hit models on epitope requirements is quite stark
(Figures 3C and 3D). In the case of the 3-hit model 90%
coverage of the Gag and Env datasets require 10 and 17
epitopes respectively.
Comparative analysis of different vaccine formulations
and multiple-hit models of vaccine requirements
Analysis of epitope requirements and incorporation of
multiple hit requirements demonstrates that it is possi-
ble to set standards for HIV vaccine trials in terms of
the mean number of epitopes generated per vaccinated
subject as a metric of potential vaccine coverage in
Figure 2 Calculation of minimum epitope coverage requirements. Interpolation of the required minimum epitope count for achieving 90%
isolate coverage for mono-valent subtype A and tetra-valent vaccine formulations (ACDE) is shown for Gag (Panel A) and Env (Panel B).
Calculated minimum epitope counts required to achieve 90% coverage all isolates in the LANL database is shown as a bar graph for Gag (Panel
C) and Env (Panel D). Color coding of the bars matches Figure 1 above (green for mono-valent, blue for di-valent, pink for tri-valent and red for
tetra-valent).
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cine insert formulations. Comparative analyses consider-
ing all possible mono-, di-, tri- and tetra-valent
formulations for all four MHRP vaccine products con-
sidered in this study were performed and are included
in Additional File 3 and Additional File 4. Notably it is
p o s s i b l et oc o m p a r et h er e l a t i v eb e n e f i t st h a tm u l t i -
valent formulations may provide for increasing the
breadth of vaccine coverage and decreasing the epitope
requirements for maximizing global (or localized) vac-
cine coverage. Tables 1 and 2 summarize the epitope
requirements for 95%, 90% and 75% coverage of the glo-
bal group M Gag and Env datasets respectively. The epi-
tope requirements for 95% and 75% coverage of any
possible incoming strain of HIV-1 have also been
included for comparison purposes as these may repre-
sent necessary, or preferred, alternative goals to the 90%
coverage limit that has been applied throughout the
prior analyses. Several important observations can be
made from this analysis. First, it is clear that there is a
large difference in the individual coverage provided by
the 4 different natural sequence products (mono-valent
analyses). This is particularly evident among the Gag
sequences where the subtype C based construct (MVA-
TZC) gives the best coverage and is most likely due a
slight overrepresentation of subtype C derived sequences
in the dataset relative to the subtypes from which the
other three natural sequences were derived. Secondly,
vaccines generating T cells that target the Gag protein
may be advantageous in comparision to Env protein tar-
geting vaccines. For any vaccine formulation valency
and any exact hit requirement model considered there
are approximately two-fold more Env epitopes required
to reach any coverage requirement than for Gag (Tables
1 and 2). The impact of Env sequence diversity on epi-
tope requirements is evident as medians of 1.9, 1.8 and
1.7 fold greater epitope requirements than Gag for cov-
erage levels of 95%, 90% or 75%, respectively (Figure 4).
Figure 3 Comparison of epitope requirements for vaccine coverage in multiple-epitope hit models. Comparisons of 1-, 2- and 3-exact hit
epitope requirement models are shown for a mono-valent product (MVA-CMDR Gag and Env inserts) assessed against a dataset of homologous
subtype (CRF01_AE) derived sequences (88 Gag sequences, Panel A; 112 Env sequences, Panel B). For contrast a tetra-valent formulation of the
products (ACDE) assessed against the entire HIV-1 group M Gag (Panel C) and group M Env (Panel D) datasets is also shown. In all graphs the 1-
hit model is represented by the blue line and symbols, the 2-hit model is the green line and symbols and the 3-hit model is the red line and
symbols. For reference, the 90% coverage point for each dataset is again denoted by a dotted line on each graph.
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the vaccine constructs considered was also for the pur-
pose of generating antibodies against native HIV
sequences. The multi-valent formulations clearly provide
a potential solution to the genetic “diversity problem”
p o s e db yH I V .F o rG a g ,a n de v e nw h e nc o n s i d e r i n ga
multi-hit model, the number of epitopes required to
reach 90% coverage of the global group M Gag sequence
database is 10 epitopes for the tetravalent formulation
and for each of the 4 possible tri-valent formulations is
10 to 12 epitopes. While this is still a considerable num-
ber of epitopes it is not beyond the capacity of the
immune system to generate such broad responses in the
context of HIV-1 natural infection [47,54]. The Env pro-
tein again demonstrates the problem of genetic diversity
that HIV-1 poses. Even for multi-valent Env
Table 1 Gag epitope coverage requirements of all possible formulations of the four natural sequence based products
for the global group M dataset.
Natural Sequence Construct Minimum number of T Cell Epitopes Required to Reach Indicated Coverage of Group M Gag
Dataset
1-Hit Model 2-Hit Model 3-Hit Model
95% 90% 75% 95% 90% 75% 95% 90% 75%
Mono-valent MVA-KEA (A) 13 10 6 20 17 12 > 20 > 20 18
Mono-valent MVA-TZC (C) 9741 4 1 2 81 9 1 6 1 2
Mono-valent MVA-UGD (D) 10 8 5 16 14 10 > 20 19 14
Mono-valent MVA-CMDR (E) 12 9 6 19 15 11 > 20 > 20 16
Di-valent KEA/TZC (AC) 6531 0 961 4 1 2 9
Di-valent KEA/UGD (AD) 7641 2 1 0 71 6 1 4 1 1
Di-valent KEA/CMDR (AE) 9741 4 1 2 81 9 1 6 1 2
Di-valent TZC/UGD (CD) 6531 0 861 3 1 1 9
Di-valent TZC/CMDR (CE) 6531 0 861 3 1 2 9
Di-valent UGD/CMDR (DE) 7641 2 1 0 71 6 1 4 1 1
Tri-valent KEA/TZC/UGD (ACD) 5439751 2 1 0 8
Tri-valent KEA/TZC/CMDR (ACE) 6439861 2 1 1 8
Tri-valent KEA/UGD/CMDR (ADE) 6531 1 961 4 1 2 9
Tri-valent TZC/UGD/CMDR (CDE) 5439751 2 1 0 8
Tetra-valent KEA/TZC/UGD/CMDR (ACDE) 5438751 1 1 0 7
Table 2 Env epitope coverage requirements of all possible formulations of the four natural sequence based products
for the global group M dataset.
Natural Sequence Construct Minimum number of T Cell Epitopes Required to Reach Indicated Coverage of Group M Env
Dataset
1-Hit Model 2-Hit Model 3-Hit Model
95% 90% 75% 95% 90% 75% 95% 90% 75%
Mono-valent MVA-KEA (A) 20 16 10 > 20 > 20 19 > 20 > 20 > 20
Mono-valent MVA-TZC (C) 20 16 10 > 20 > 20 19 > 20 > 20 > 20
Mono-valent MVA-UGD (D) 18 14 9 > 20 > 20 17 > 20 > 20 > 20
Mono-valent MVA-CMDR (E) > 20 16 10 > 20 > 20 19 > 20 > 20 > 20
Di-valent KEA/TZC (AC) 14 11 7 > 20 18 13 > 20 > 20 19
Di-valent KEA/UGD (AD) 12 10 6 20 17 12 > 20 > 20 17
Di-valent KEA/CMDR (AE) 13 10 6 > 20 17 12 > 20 > 20 18
Di-valent TZC/UGD (CD) 12 9 6 19 16 11 > 20 > 20 17
Di-valent TZC/CMDR (CE) 14 11 7 > 20 18 13 > 20 > 20 19
Di-valent UGD/CMDR (DE) 13 10 6 20 17 12 > 20 > 20 17
Tri-valent KEA/TZC/UGD (ACD) 10 8 5 17 14 10 > 20 19 14
Tri-valent KEA/TZC/CMDR (ACE) 11 8 5 17 14 10 > 20 20 15
Tri-valent KEA/UGD/CMDR (ADE) 11 8 5 17 14 10 > 20 19 15
Tri-valent TZC/UGD/CMDR (CDE) 10 8 5 17 14 10 > 20 19 15
Tetra-valent KEA/TZC/UGD/CMDR (ACDE) 9751 5 1 2 92 0 1 7 1 3
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90% coverage of the global group M Env sequence data-
base ranges from 7 to 8 epitopes for the 1-hit model
and rises to 17 to 20 epitopes for the 3-hit model. Gen-
erating this breadth of response presents a possibly
intractable problem as it may be beyond the capacity of
the immune system to generate such a high epitope
number against a single protein. This result however
should not be interpreted as a reason to preclude the
inclusion of Env proteins in T cell based vaccine modal-
ities. The data shown in Figure 3B clearly demonstrates
that an appropriately selected, subtype matched, natural
Env sequence may provide sufficient coverage within the
homologous subtype with as few as 5 epitopes. There-
fore, counting the number of epitopes generated by dif-
ferent vaccines and factoring the diversity provided by
the sequence of the vaccine inserts will be critical to
assessing the coverage provided for a specific HIV
epidemic.
Further refinements of vaccine coverage analysis
While use of the mean 10-mer coverage that any given
vaccine insert sequence provides is a practical solution
to rapidly determining the theoretical epitope require-
ments, there are potential further refinements that can
be made when considering vaccine coverage analysis.
Figure 5A shows how the 10-mer coverage of any vac-
cine insert against a given query dataset, in this case the
subtype A Gag protein coverage of the LANL group M
Gag dataset, is a mean of the total positional coverage.
The mono-valent subtype A coverage shown in red is a
series of peaks and troughs representing regions of high
and low depth of coverage across the group M Gag
dataset. Also shown, superimposed in blue on the same
figure, is the additional coverage provided by a tetra-
valent ACDE vaccine formulation. The mean coverage
for each vaccine product, mono-valent A (21.3%) and
tetra-valent ACDE (48.7%), is the overall mean of an
uneven discrete probability distribution spanning the
entire protein. In Figure 5B examples are shown of how
the exact position of an epitope can have a profound
influence on the depth of coverage it can provide. Sites
Figure 4 Comparison of Env and Gag epitope coverage
requirements. Shown is the ratio of Env:Gag epitope requirements
to reach 95%, 90% or 75% coverage of the global HIV-1 group M
datasets for any given formulation of the four natural sequence-
based products. Regardless of the valency of the vaccine product
Env consistently requires approximately two-fold more epitopes to
be generated than Gag to reach any given level of coverage.
Figure 5 Illustration of positional coverage for group M Gag
sequences by a mono-valent versus a tetra-valent vaccine
product. Positional coverage of a group M Gag dataset (2385
sequences) is shown for the mono-valent subtype A vaccine
product (MVA-KEA) and a tetra-valent formulation of the four
products (ACDE). The fraction of variants with exact 10-mer
matching in 493 successive windows of 1 amino acid across the
Gag dataset (2385 proteins aligned to HXB2) for the monovalent
formulation (red) and tetra-valent formulation (blue) is shown (Panel
A). Potential examples of high- and low-depth of coverage epitopes
are superimposed upon the positional coverage diagram to
illustrate breadth and depth of coverage (Panel B).
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contrast to sites of low depth of coverage epitopes
shown in green. This example illustrates how the depth
of a T cell epitope response is as important as knowing
the breadth of the response. Two or three epitopes tar-
geting highly conserved regions of a protein may be as
effective as 8 to 10 epitopes targeting only sites of low
coverage. Therefore not only counting the number of
epitopes generated by a vaccine product, but also know-
ing their mapped positions adds further refinement to
interpreting the potential coverage provided by a vaccine
product.
As an example of how to practically assess the theore-
tical coverage that may be provided by a vaccine, data is
presented from epitope mapping studies performed dur-
ing a recently completed vaccine trial (RV158) involving
one of the native sequence constructs (MVA-CMDR)
considered in the prior analyses [53]. Epitope mapping
was performed for Gag and Env from 2 different trial
participants, the results of which are outlined in Addi-
tional File 5 and Additional File 6 for each participant
r e s p e c t i v e l y .A ss h o w n ,o n eparticipant demonstrated a
relatively broad response of 6 T cell epitopes in total (4
in Env and 2 in Gag), while the second subject demon-
strated a narrow T cell response (2 epitopes) with a sin-
gle epitope each in Env and Gag respectively. Using the
methods described above and a 1-hit epitope require-
ment model the coverage provided by the response gen-
erated in each of these two participants is shown in
Table 3. The effect of increased breadth upon HIV
strain coverage is striking. The participant that gener-
ated 6 epitopes would have a 97.1% probability of mak-
ing at least one exact epitope match with any incoming
HIV strain from the homologous subtype (CRF01_AE)
and a 67.7% probability of making an exact match with
any global strain of HIV. In contrast, the participant
with a single epitope against both Gag and Env would
have 73.4% and 34.1% probability of making one exact
epitope match within the homologous subtype or with a
global strain of HIV respectively.
Empirical assessment of T cell-based vaccine coverage
As a final refinement to the coverage analysis the
sequence of the peptide(s) recognized from the vaccine
product(s) can be used to directly query the database
for depth of coverage independently. This represents
both the most stringent form of coverage analysis and
the most technically demanding and laboratory intensive
analysis. Once the T cell epitopes have been enumer-
ated, further studies can be performed to identify and
confirm the peptides and/or peptide overlaps that are
recognized. These short sequences can be used to screen
databases and datasets for a more precise determination
of the coverage provided. This affords a much greater
precision for the coverage analysis calculations because
as shown in Figure 5B, epitopes may fall on regions of
high or low depth of coverage. Depending upon sample
availability, the cross-reactive capacity of these responses
with peptides representing other common variants uti-
lized by HIV can provide a stringent picture of epitope
depth of coverage. Empirical determination remains the
only real means of assessing cross-reactivity since there
currently no reliable computational methods which can
gauge the cross-reactivity of T cells specific for a given
epitope. Using the two examples used above (Additional
File 5 and Additional File 6) the sequences of the pep-
tides recognized were used to scan the global group M
Gag and Env sequence datasets and the homologous
subtype (CRF01_AE) for exact 10-mer matches within
the 6 mapped epitopes (2 in Gag, and 4 in Env). Table 4
shows the exact 10-mer coverage provided by each of
the 6 T cell epitopes identified in a vaccine trial partici-
pant. The Gag epitope VDRFYKTLRAE provides 89.7%
and 42.1% coverage of the homologous subtype and glo-
bal group M Gag epidemics respectively and would be
considered a high depth of coverage epitope particularly
for the CRF01_AE subtype. The second Gag epitope
(NFPQSRPEPTAPPAE) also provides a medium level of
coverage for subtype-specific and the overall group M
Table 3 Theoretical HIV isolate coverage provided by





Gag Env Total Gag Env Total
Number of Epitopes 2 4 6 1 1 2
Intra-subtype
Coverage




41.8% 44.5% 67.7% 23.7% 13.7% 34.1%






(CRF01_AE) (All Group M)
Gag VDRFYKTLRAE 89.7% 42.1%
NFPQSRPEPTAPPAE 58.6% 42.4%
All Gag 95.7% 66.7%




All Env 69.9% 14.7%
Overall Gag and Env 98.7% 71.6%
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trasts with the Env epitopes, which vary dramatically in
their coverage of the homologous subtype and the over-
all group M Env datasets. Three of the Env epitopes
would provide 45.1%, 30.6% and 20.7% coverage of the
homologous subtype, putting them in the intermediate
range of depth of coverage. However, the coverage pro-
vided by these epitopes for the group M global Env
dataset would be only 2.8% to 6.9%, hence putting them
in the low depth of coverage category for global Env
diversity. The remaining Env epitope represents a
unique sequence in the database and provides no exact
10-mer coverage. The overall potential coverage deter-
mined by both methods - enumeration of the epitopes
(Table 3) and epitope mapping and sequence dataset
screening (Table 4) - arrived at remarkably similar
results. Overall coverage calculated by epitope enumera-
tion for the homologous subtype and the global M-
group was 97.3% and 67.7% respectively, which is com-
parable to the epitope mapping and screening method
determinations of 98.7% and 71.1% for the correspond-
ing datasets. This data therefore provides empirical vali-
dation of the epitope enumeration method as a rapid
means of determination potential coverage in the setting
of vaccine trial assessment. The enhancement that
increased breadth of recognition provides is exemplified
by the 69.9% overall coverage provided by the 4 Env epi-
topes corresponding to the homologous subtype. This
implies that at least within a subtype, Env sequence
diversity may not present an intractable problem for T
cell-based vaccine development.
Discussion
In this study it has been demonstrated that measure-
ment and analysis of the breadth of the T cell response
- the number of discrete T cell epitopes - generated by
a vaccine provides an important metric for HIV vaccine
assessment. Analysis of the breadth of T cell coverage
not only illustrates the problem that HIV genetic diver-
sity presents to the immune system, but it also demon-
strates that increasing the breadth of coverage can
amplify the capacity of even natural sequence-based vac-
cine products to cope with viral diversity. Practical
metrics can be set prior to the commencement of a vac-
cine trial that take into account both the HIV sequence
content in the vaccine product and the diversity of HIV
in particular target settings. Importantly, the relative
capacities of different multi-valent formulations to gen-
erate sufficient epitope coverage can be compared
directly. While the analyses presented here are limited
to exact 10-mer matches as epitope hits this was consid-
e r e dt ob ear e a s o n a b l ec o m p r o m i s eb e t w e e nt h em e d -
ian CD8
+ T cell epitope length (9-10 amino acids) and
the minimal core of a CD4
+ T cell epitope (10-12 amino
acids). However, shorter or longer epitope windows (8,
9, 10, 11 or 12 amino acids) and more relaxed matching
requirements (1 or 2 tolerated amino acid mismatches)
could be incorporated as desired into this analysis. It
was felt that the requirements used here represent a
more conservative approach and hence may in fact
over-estimate the epitope requirements since no mis-
matches are tolerated. The studies of Korber et al. [26],
using computationally generated mosaic vaccine insert
sequences clearly demonstrate a progression to
increased vaccine coverage as matching requirements
are relaxed and as smaller epitope windows are consid-
ered [26,32]. Importantly, the practical application of
epitope mapping in vaccine evaluation demonstrates
that understanding the depth of individual epitope cov-
erage provides an added layer of sophistication to vac-
cine coverage assessment. Preclinical studies
investigating the cellular immunogenicity of mosaic con-
structs and comparing them with natural sequence con-
structs unequivocally demonstrates the importance of
breadth and analysis as a metric of the T cell response
[55,56].
Empirical data has begun to emerge that implicates T
cell epitope breadth as a critical parameter in both the
natural control of HIV-1 infection and in pre-clinical
testing of different vaccine strategies and modalities. In
cross-sectional studies of naturally HIV-1 infected, treat-
ment naïve human subjects, investigators have identified
the breadth of the cellular immune response, rather
than the magnitude of the response, as the primary dis-
criminator of effective immune control as measured by
set-point viral load [43,45,49,50,57,58]. Furthermore, the
transmission of escape variants for Gag-specific CD8
+ T
cell epitopes is associated with reduced viral load in
linked subjects, and if multiple epitopes are targeted the
likelihood of epitope reversion is diminished
[49,50,59-61]. Computational analysis and epitope pre-
diction based on HLA type and HIV proteome sequence
in a large cohort of 302 subjects has also shown that
epitope repertoire and breadth is critical to viral load
control [48]. The seminal study by Liu and co-workers
[51] demonstrated immune control of an SIV challenge
by a T cell-based vaccine in rhesus macaques and linked
breadth of vaccine generated T cell responses with rela-
tive efficacy of different immunogens. This study estab-
lished for the first time a correlate of cellular immunity
and mitigation of disease outcome in a realistic SIV
challenge model. To date there is no clear indication of
the exact breadth of the T cell response that the human
immune system is capable of generating against the Gag
and Env proteins considered here. However, pre-clinical
data from the rhesus macaque model suggest that 20 or
more T cell epitopes can readily be generated by vacci-
nation with a non-replicating viral vector [55,56]. In
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more epitopes can be detected within a single individual
when the entire HIV proteome is considered [47,54].
Whether such breadth is practically attainable in the set-
ting of a human vaccine study remains to be proven. In
this study the generation of greater than 20 epitopes per
protein per vaccinee was considered an intractable pro-
blem for the immune system. Hence, 20 epitopes was
the limit of calculation for epitope breadth in all ana-
lyses presented here.
It is therefore not surprising that increasing the
breadth of T cell recognition might be associated with
better control of viremia, since the more epitopes recog-
nized the more difficult it would be for the virus to find
multiple escape mutations of relatively low fitness costs.
A less obvious and perhaps more biologically cogent
reason behind the breadth association with viral control
is that certain T cell epitopes may be more effective
than others. Prior studies have implicated T cells target-
ing certain gene products of the virus (e.g. Gag) as
being associated with better control of viremia
[43,45,48-50,62]. Further studies have refined these ana-
lyses to regions of certain gene products and even parti-
cular epitopes. The reasons for this phenomenon could
include any or all of the time and timing of gene pro-
duct expression, the HLA background of the infected
individual, the availability of generated epitopes for anti-
gen processing and presentation, and the TCR reper-
toire. Aside from certain epitopes (particularly in the
Gag and Nef proteins) presented by alleles frequently
associated with control of viremia (HLA-B2705, -B5701/
03, -B5801; [49,50,62,63]) there is a paucity of knowl-
edge relating to exactly which epitopes provide the best
protection. Without ap r i o r iknowledge of epitopes that
should be targeted by any given individual, the multi-hit
models of vaccine assessment presented here provides a
potential alternative. While the single-hit model assumes
that all epitopes may be equally effective at mediating
infected cell recognition, the 2-hit and 3-hit models
assume that only one-half and one-third of all possible
T cell epitopes respectively are actually effective in med-
iating T cell recognition of virally infected target cells
and inhibiting viral replication. The data presented here
show how the consideration of multiple hit models
places a greater onus upon any given vaccine product to
p r o v i d ea p p r o p r i a t ec o v e r a g eo fa l lp o s s i b l ei n c o m i n g
strains of HIV-1. Using the natural sequence based vac-
cine constructs developed in the MHRP it is shown that
if used in mono-valent formulations there is sufficient
coverage of the homologous subtype, even within the
Env protein if sufficient breadth of the immune response
(4-6 epitopes) is generated. Furthermore, multi-valent
formulation of the products potentially provides ample
coverage (> 90% of strains) even for the global HIV-1
group M epidemic for both Gag and Env when consid-
ering the single-hit model. The greater diversity within
the Env protein compared with Gag is reflected in the
generalized requirement for nearly twice the number of
epitopes in Env to reach any level of equivalent cover-
age. However, if a multi-hit model proves to be an accu-
rate description of T cell requirements for an effective
vaccine, then the requirements to meet any level of cov-
erage increase dramatically. For mono-valent formula-
tions both the 2- and 3-hit models place such high
requirements upon both Gag (8-12 epitopes for 75%
coverage using a 2-hit model) and Env (17-19 epitopes
for 75% coverage using a 2-hit model), that generating
sufficient breadth would be a difficult proposition. Con-
sidering a 3-hit model and 90% coverage of the global
epidemic the epitope breadth requirements present what
is most likely an insurmountable challenge for the
immune system (> 20 epitopes required per protein).
Multi-valent formulation of the natural sequences does
provide increased benefit in terms of generating poten-
tially more cross-reactive cells, especially when consider-
ing subtype-specific vaccine coverage. However, as far as
global group M coverage is concerned multi-valent for-
mulation and delivery of the natural sequence based
products is the most realistic means of ensuring suffi-
cient coverage if multiple exact T cell epitope matches
are required for vaccine efficacy.
While quite sobering, these data serve to underscore
the practical requirements for a T cell-based vaccine to
be efficacious in a broader setting and also provides
meaningful tools for assessing those requirements. This
kind of analysis could also be directly applied to any
kind of computationally derived vaccine insert
sequences such as consensus, center-of-tree, mosaic,
conserved element or string epitope concatenated
sequences [26,29-41]. Such approaches offer a means of
maximizing vaccine coverage at the single epitope level
and by direct inference would also improve coverage for
multiple epitope and multiple-hit requirement models of
vaccine coverage. The only caveat that needs to be ful-
filled for the computational approaches is proof-of-con-
cept studies in human trials that verify the products can
indeed be immunogenic. Epitopes targeting sites of
high-depth rather low depth of coverage is embodied in
the mosaic, center-of-tree and conserved elements vac-
cine approaches. Since, the processing of antigens that
ultimately results in the presentation of epitopes is not
fully understood, a critical iss u ef o rt h ec e n t e r - o f - t r e e
and conserved elements vaccine constructs in particular
is a strategy for assembling the peptide fragments for
operational vaccine delivery. Simple concatenation of
peptide fragments to produce embedded epitopes in the
context of the assembled fragments is not sufficient as
was demonstrated by the poor immunogenicity observed
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sequence based products have at least been shown to be
immunogenic for very broad T cell responses in pre-
clinical studies in primates [55,56]. The present study
has been restricted to the inclusion of natural sequence-
based products in the MHRP product development plan
(MVA vector-based). These products have all been
shown to be immunogenic for T cell responses in pre-
clinical studies and in particular, the MVA-CMDR pro-
duct has been shown to be immunogenic for T cell
responses as both a prime and a boost in human phase
I clinical trials [31,53,64]. An added rationale for at least
maintaining the native Env protein is conformation for
antibody production. A critical assumption that the
multi-valent analyses have been predicated upon is the
notion that each unique variant of an epitope within the
cocktail is either immunogenic or cross-reactive with
other variants of the same epitope in the cocktail. In
cases where this assumption does not hold, the multi-
valent analysis presented here may overestimate epitope
depth of recognition. However, as discussed previously
this possible over-estimation may be counter-acted
numerically by the high stringency of exact epitope
recognition that the model is based upon. In the setting
of a vaccine trial mapping of the response permits ana-
lysis not only of the number of T cell epitopes, but also
the epitope repertoire and depth of recognition. As
shown in this study accurately mapping T cell responses
adds the important dimension of depth of epitope
recognition to the analysis. Knowledge of at least the
approximate minimal epitope (down to 15-mer resolu-
tion), allows both a more accurate theoretical estimation
of potential depth of recognition and further experimen-
tal validation of the cross-reactivity of a response using
designed peptide variants.
The T cell epitope breadth analysis presented here
also highlights the issue of formulation and delivery of
multi-valent vaccine products. While the simplest
approach for delivery would be co-formulation for both
priming and boosting vaccinations, a multi-valent pro-
duct may benefit from priming with a single valency
product and sequential boosting with the heterologous
products. Such an approach might focus the T cell
response upon the boosting of cross-reactive T cell
responses at the expense of boosting potentially immu-
nodominant responses with limited cross-reactivity. The
heterologous prime-boost approach has already been
shown to be effective in generating high magnitude T
cell responses in several human vaccine trials [64-66].
The recent successful Thai phase III trial (RV144) pro-
vides an important example of how the role of T cells
and their cross-reactive capacity must be taken into
account even in the setting of a heterologous prime-
boost approach involving a recombinant protein as one
of the formulations [17]. A vaccine that generates anti-
bodies as the likely mediator of its efficacy would still
require appropriate T cell help for formation of an ade-
quate antibody repertoire [67-70]. The HIV vaccine field
is currently moving forward from the pre-clinical phase
into the clinical testing phase of vaccines with increasing
complexity in terms of both formulation and the
mechanism(s) by which they mediate protective effects.
The role of T cells in all of these scenarios must be
addressed whether it is indirectly as help for antibody
production against multimeric envelope proteins, or
directly as effector or effector-memory cells generated
by recombinant viral vectors [2,6,51,71,72].
There are several further refinements and caveats that
need to be kept in mind when such analysis is per-
formed. An implicitly important variable in this analysis
is the query database. This study has made use of the
LANL HIV sequence database without bias for the pre-
valence of any given subtype. However, this database is
heavily biased towards subtypes B and C in terms of
raw sequence constituency. Hence, more nuanced ana-
lyses for vaccines targeted for East Africa, West Africa,
Asia and eastern Europe, would benefit from more
expansive query datasets that include better sampling of
subtypes A, D, G, CRF01_AE and CRF01_AG. This
highlights the importance of sequence sampling and the
dataset used as the basis for the coverage requirement
calculations. Experimentally, there is also a need to dis-




+ T cells are generally considered the
effector cells responsible for viral control and clearance
and therefore the specific contribution of these cells to
the overall should be specifically assessed. The most
robust and practical assay for epitope enumeration and
identification in a vaccine trial is the IFNg Elispot assay.
However, this assay is not readily adaptable to discern-
ing the phenotype of the responding cells without signif-
icant sample usage. Therefore, high throughput flow
cytometry-based assays that can measure epitope depth
and breadth as well as provide high content phenotypic
analysis of the responding cell populations are required.
Conclusions
In summary, we have shown here that appraisal of epi-
tope breadth and depth of recognition should be an
important metric that is considered when laboratory
assessment of HIV vaccine trials is performed. Further-
more, the incorporation of a multi-hit model into the
theoretical breadth analysis helps to set the metrics for
broadly specific T cell responses in the absence of
mechanistic data that explains the biological underpin-
nings of why high breadth responses may be advanta-
geous. The suitability for a particular vaccine and multi-
valent formulation can be also assessed during the
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execution phase. Moreover, this study shows that multi-
valent formulation, or heterologous prime-boost strate-
gies, may extend the utility of vaccine products based
upon natural sequences. While it is clearly shown that
mono-valent natural sequence based products face a
potentially intractable problem for providing appropriate
coverage for the global HIV-1 pandemic, multi-valent
formulation can improve the utility of these extant vac-
cine products, especially in an epidemic consisting of a
single subtype. Given that computationally designed vac-
cine products optimized for maximizing coverage, such
as mosaic products, will soon be tested in human clini-
cal trials it remains paramount that robust and practical
breadth assessment is included in the testing schema for
comparing and contrasting these and other approaches
for successful HIV vaccine implementation.
Additional material
Additional file 1: Subtype and isolate sequence of origin of the
natural sequence-based HIV vaccine products assessed in the study.
Additional file 2: Comparison of Epicover algorithm with a “hit/no-
hit” model of N-mer epitope identity matching. A stringent “hit/no-
hit” model of 10-mer coverage was applied to a dataset of 2285 Gag
sequences using a tetra-valent ACDE natural sequence vaccine
formulation as the query set. As shown below a near-Gaussian
distribution of the percent coverage of all isolates in the dataset was
obtained. Near identical mean coverage results were obtained using the
Epicover algorithm (as implemented in the LANL HIV Sequence
Database) and a larger dataset of 3585 Gag sequences. While a broad
distribution of “hits per isolate” was obtained (range = 13%-75%), the
near identical mean coverage results for the Epicover algorithm and the
“hit/no-hit” model resulted in no difference between the two methods
for the calculation of epitope coverage requirements and the multiple
epitope hit requirement model.
Additional file 3: Global group M Gag coverage analysis. Potential
HIV isolate coverage provided by mono-valent (panels A, B and C), di-
valent (panels D, E and F) and multi-valent (Panels G, H and I)
formulations of the four natural sequence based products is shown.
Theoretical coverage (90% in the examples shown here) is profoundly
dependent upon the number of epitopes generated and the number of
exact epitope (10-mer) matches that are required for infected cell
recognition. For example if a 1-Hit model is considered, then the tetra-
valent product would reach 90% coverage by generating four epitopes
per subject on average (Panel G, orange diamonds). In contrast, if a 3-Hit
model is considered the mono-valent subtype A product does not reach
90% coverage even if 20 epitopes are generated on average per subject
(Panel C, blue circles).
Additional file 4: Global group M Env coverage analysis. Potential
HIV isolate coverage provided by mono-valent (Panels A, B and C), di-
valent (panels D, E and F) and multi-valent (panels G, H and I)
formulations of the four natural sequence based products is shown.
Theoretical coverage (90% in the examples shown here) is again
dependent upon the number of epitopes generated but there is a much
greater epitope requirement than for Gag. For example if a 1-Hit model
is considered, then the tetra-valent product would reach 90% coverage
by generating 7 epitopes per subject on average (Panel G, orange
diamonds). If a 3-Hit model is considered the mono-valent subtype
products face an intractable problem with extreme epitope requirements
for 90% global coverage (Panel C). Even the multi-valent products have
stringent epitope requirements (17-20) for reaching 90% coverage (Panel
I).
Additional file 5: Gag epitope mapping for post-in vitro stimulated
cells from a vaccine trial responder subject. PBMC from a vaccinee in
the RV158 trial (received 3x rMVA-CMDR) were subjected two rounds of
in vitro stimulation, first with rMVA-CMDR for 14 days, then with
autologous, irradiated BLCL pulsed with peptide pools matching the Gag
(CM240) insert in the vaccine. Each stimulation cycle was 14 days, with
rIL-7 added during the first week and rIL-2 added during the second
week. Effector cells were tested for responses to a matrix of peptides (11
× 11 peptide pools) matching the Gag insert sequence. Epitopes were
counted and identified from the de-convoluted peptide matrix (Panels A
and B) in an IFN-g Elispot assay. Two epitopes were identified within the
Gag-specific effector cells and are shown in Panel C.
Additional file 6: Env epitope mapping for post-in vitro stimulated
cells from a vaccine trial responder subject. PBMC from a vaccinee in
the RV158 trial (received 3x rMVA-CMDR) were subjected two rounds of
in vitro stimulation, first with rMVA-CMDR for 14 days, then with
autologous, irradiated BLCL pulsed with peptide pools matching the Env
(CM235) insert in the vaccine. Each stimulation cycle was 14 days, with
rIL-7 added during the first week and rIL-2 added during the second
week. Effector cells were tested for responses to a matrix of peptides (14
× 13 peptide pools) matching the Env insert sequence. Epitopes were
counted and identified from the de-convoluted peptide matrix (Panels A
and B) in an IFN-g Elispot assay. Two epitopes were identified within the
Env-specific effector cells and are shown in Panel C.
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